The rising popularity in GLP-1 agonists for diabetes has sparked a discussion about delivery methods : skin-applied devices versus capsules. Usually , GLP-1 drugs were only available in oral form, but the introduction of patches offers a new way. Transdermal systems might suit individuals with is